Abstract
The survival impact of single-agent treatment with docetaxel, the standard regimen for relapsed patients with non-small cell lung cancer (NSCLC), remains modest. We conducted a randomized phase II study to evaluate the efficacy and safety of the combination of docetaxel and S-1 in the second-line setting. Patients with relapse of NSCLC after first-line platinum-based chemotherapy were randomly assigned to docetaxel alone (60 mg/m, day 1, q3 weeks; arm A) or a combination of docetaxel (40 mg/m, day 1, q3 weeks) and S-1 (80 mg/m, days 1-15; arm B). The primary end point was response rate, whereas secondary endpoints included overall survival, progression-free survival, and toxicity. Between 2005 and 2008, a total of 60 patients were enrolled in the study. The objective response rates were 20.7% and 16.1% in arms A and B, respectively (p = 0.81). Progression-free survival was comparable in the two arms (median: 3.7 versus 3.4 months, p = 0.27), whereas overall survival time was longer in arm A (22.9 versus 8.7 months, p = 0.02). The major toxicity was myelosuppression with grade > or =3 neutropenia in 89.7% of patients versus 64.5% in arms A and B, respectively. This study suggests that docetaxel monotherapy should continue to be ...Continue Reading
References
May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H KunitohT Taguchi
Oct 18, 2001·Anti-cancer Drugs·Y TakedaM Eriguchi
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joyce O'ShaughnessyRobert Leonard
Oct 30, 2003·Cancer·Ji-Youn HanJin Soo Lee
Aug 25, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katsuyuki HottaMitsune Tanimoto
Mar 10, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tamila Kindwall-KellerMiguel A Villalona-Calero
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Mar 25, 2006·International Journal of Cancer. Journal International Du Cancer·Yoshiyuki WadaMasakazu Fukushima
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Katsuyuki Hotta, Keitaro Matsuo
Sep 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hiroshi SuehisaHiroshi Date
Sep 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Shinji AtagiHikotaro Komatsu
Sep 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Riichiroh MaruyamaMasahiro Fukuoka
Nov 26, 2008·Lancet·Edward S KimJean-Yves Douillard
Jan 24, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K TakedaN Saijo
Mar 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo Di MaioCesare Gridelli
Jan 14, 2010·Cancer Chemotherapy and Pharmacology·Kazuhiro YanagiharaMasanori Fukushima
Citations
May 25, 2011·Cancer Chemotherapy and Pharmacology·Wei-Xiang QiYang Yao
Feb 22, 2012·Lung·Kouichi InoueMasahiro Takeuchi
Feb 1, 2014·Japanese Journal of Clinical Oncology·Kazuhiko YamadaTomoaki Hoshino
Jan 27, 2016·Expert Opinion on Drug Safety·Omar Abdel-RahmanShaimaa Essam-Eldin
Feb 4, 2016·Future Oncology·Omar Abdel-Rahman, Hesham ElHalawani
Jan 14, 2016·Cancer Chemotherapy and Pharmacology·Mark StrohJin Jin
May 9, 2014·Asia-Pacific Journal of Clinical Oncology·Hidekazu SuzukiIchiro Kawase
Aug 12, 2014·Expert Opinion on Pharmacotherapy·Masaaki Kawahara
Nov 30, 2014·Drug Discovery Today·Neha SinghJagat R Kanwar
Dec 24, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Naoyuki NogamiKatsuyuki Kiura
Jan 24, 2015·Japanese Journal of Clinical Oncology·Shinnosuke IkemuraKenzo Soejima
Aug 31, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Keisuke AoeKatsuyuki Kiura
Sep 27, 2014·Clinical Therapeutics·Ying JinXinmin Yu
Dec 17, 2016·The Tohoku Journal of Experimental Medicine·Xin SunCheng-Bo Han
Oct 5, 2011·Oncology·Kenji AkieUNKNOWN Hokkaido Lung Cancer Clinical Study Group
Dec 18, 2019·Journal of Clinical Medicine·Koichi TakayamaYoichi Nakanishi